| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide a cancer therapeutic agent useful for treating patients suffering from cancer in which information on a cancer antigen for the cancer antigen-specific vaccine therapy or cancer in which the type of human leuchocyte antigen (HLA) is incompatible with the vaccine therapy. <P>SOLUTION: An antigen-specific Th1 cell is produced by adding a type 1 cytokine to a small amount of peripheral blood obtained from the patient suffering from cancer and carrying out culture in the presence of an antigen activating the T cell other than the cancer antigen. A tumor-specific CTL is induced in a living body as a cancer-carrying host by administering the antigen used for inducing the antigen-specific Th1 cell and the antigen-specific Th1 cell in combination. <P>COPYRIGHT: (C)2011,JPO&INPIT |
